- Home
- LCTX vs NTHI Comparison
LCTX vs NTHI Comparison
Compare LCTX & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- NTHI
- Stock Information
- Founded
- LCTX 1990
- NTHI 2008
- Country
- LCTX United States
- NTHI United States
- Employees
- LCTX N/A
- NTHI N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- LCTX Health Care
- NTHI Health Care
- Exchange
- LCTX Nasdaq
- NTHI Nasdaq
- Market Cap
- LCTX 107.3M
- NTHI 110.9M
- IPO Year
- LCTX N/A
- NTHI N/A
- Fundamental
- Price
- LCTX $1.03
- NTHI $4.97
- Analyst Decision
- LCTX Strong Buy
- NTHI
- Analyst Count
- LCTX 5
- NTHI 0
- Target Price
- LCTX $4.20
- NTHI N/A
- AVG Volume (30 Days)
- LCTX 1.6M
- NTHI 547.1K
- Earning Date
- LCTX 08-07-2025
- NTHI 01-01-0001
- Dividend Yield
- LCTX N/A
- NTHI N/A
- EPS Growth
- LCTX N/A
- NTHI N/A
- EPS
- LCTX N/A
- NTHI N/A
- Revenue
- LCTX $9,557,000.00
- NTHI $79,990.00
- Revenue This Year
- LCTX N/A
- NTHI N/A
- Revenue Next Year
- LCTX $232.66
- NTHI N/A
- P/E Ratio
- LCTX N/A
- NTHI N/A
- Revenue Growth
- LCTX 19.42
- NTHI 13.52
- 52 Week Low
- LCTX $0.37
- NTHI $3.20
- 52 Week High
- LCTX $1.21
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- LCTX 53.25
- NTHI N/A
- Support Level
- LCTX $0.93
- NTHI N/A
- Resistance Level
- LCTX $1.02
- NTHI N/A
- Average True Range (ATR)
- LCTX 0.08
- NTHI 0.00
- MACD
- LCTX -0.01
- NTHI 0.00
- Stochastic Oscillator
- LCTX 35.71
- NTHI 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").